| Literature DB >> 35451510 |
Vinzent Kevin Ortner1, Nhi Nguyen1,2, Jonathan R Brewer2, Vita Solovyeva2,3, Merete Haedersdal1, Peter Alshede Philipsen1.
Abstract
PURPOSE: Conventional oral antifungal therapies for onychomycosis (OM) often do not achieve complete cure and may be associated with adverse effects, medical interactions, and compliance issues restricting their use in a large group of patients. Topical treatment can bypass the systemic side effects but is limited by the physical barrier of the nail plate. Ablative fractional laser (AFL) treatment can be used to improve the penetration of topical drugs into the nail. This study visualized the effects of laser ablation of nail tissue and assessed their impact on the biodistribution of a fluorescent dye in healthy and fungal nail tissue.Entities:
Keywords: fluorescence microscopy; fractional CO2 laser; laser-assisted drug delivery; nail fungus; onychomycosis
Mesh:
Substances:
Year: 2022 PMID: 35451510 PMCID: PMC9544547 DOI: 10.1002/lsm.23541
Source DB: PubMed Journal: Lasers Surg Med ISSN: 0196-8092
Overview of studies on clinical and preclinical laser‐assisted drug delivery in healthy and diseased nail tissue
| Year and author | Sample size | Condition | Compound | MW (g/mol) | Vehicle | Application | Laser type and device | Settings | Density |
|---|---|---|---|---|---|---|---|---|---|
| 2013 | 2 | Onychodystrophy | Desoximetasone 0.25% | 376.4 | Lotion | Once daily | CO2 (10,600 nm); | 160 mJ | 150 spots cm−2 |
| Mosaic eCO2, Lutronic | (3 passes) | ||||||||
| EH Lim | |||||||||
| 2013 | 9 | Onychomycosis | Amorolfine 5% | 317.5 | Lacquer | Once weekly | Er:YAG (2,940 nm); Etherea, Industra | 50 mJ mtz−1 | N.A. |
| (number of passes dependent on nail thickness and patient tolerability) | |||||||||
| OO | |||||||||
| 2014 | 24 | Onychomycosis | Amorolfine 5% | 317.5 | Cream | Once daily | CO2 (10,600 nm); | 160 mJ | 150 spots cm−2 |
| Mosaic eCO2, Lutronic | (2–3 passes) | ||||||||
| EH Lim | |||||||||
| 2015 | 7 | Onychomycosis | MAL 16% | 181.6 | Cream | Before PDT | CO2 (10,600 nm); – | 160 mJ | 600 µm spacing between mtz |
| (3 stacks) | |||||||||
| GB deOliveira | |||||||||
| 2015 | 75 | Onychomycosis | Terbinafine 1% | 291.4 | Cream | Once daily | CO2 (10,600 nm); | 99 mJ | 410 spots cm−2 |
| 2030CI, Wuhan Qi Zhi Laser Technology | (2–6 passes) | ||||||||
| AK Bhatta | |||||||||
| 2016 | 60 | Onychomycosis | Luliconazole 1% | 354.3 | Cream | Once daily | CO2 (10,600 nm); | 10–15 mJ | 10% |
| BR Zhou | AcuPulse, Lumenis | (1–3 stacks) | |||||||
| 2016 | 9 | Onychomycosis | Amorolfine 5% | 317.5 | Lacquer | Twice weekly | Er:YAG (2,940 nm); | 35–62 J cm−2 | 120 spots cm−2 |
| J Zhang | Sciton | (3 passes) | |||||||
| 2017 | 31 | Onychomycosis | Terbinafine 1% | 291.4 | Cream | Once daily | CO2 (10,600 nm); | 15 mJ | 15% |
| AcuPulse; Lumenis | (multiple passes) | ||||||||
| J Shi | |||||||||
| 2017 | 54 | Onychomycosis | (a) ALA 20% | (a) 167.6 | (a) Cream | (a) Before PDT | CO2 (10,600 nm); | 150 mJ | 3% |
| (b) Amorolfine 5% | (b) 317.5 | (b) Lacquer | (b) Once weekly | Lumenis Ultrapulse | (single pass) | ||||
| A Koren | |||||||||
| 2018 | 102 | Onychomycosis | (a) Tazarotene 0.1% | (a) 351.5 | (a) Gel | Once daily | CO2 (10,600 nm); | Power 10 W | 700 µm spacing between mtz |
| Smartxide DOT, DEKA, Italy | (3 stacks) | ||||||||
| (b) Tioconazole 28% | (b) 387.7 | (b) Solution | |||||||
| EB Abd El‐Aal | |||||||||
| 2019 | 30 | Onychomycosis | Tioconazole 28% | 387.7 | Lacquer | Twice daily | CO2 (10,600 nm); | Power 11–15 W | 500 µm spacing between mtz |
| RA El‐Tatawy | (1–3 stacks, | ||||||||
| 1–3 passes) | |||||||||
| Smartxide DOT, DEKA, Italy | |||||||||
| 2020 | 21 | Onychomycosis | Methylene Blue 2% | 319.9 | Solution | Before PDT | CO2 (10,600 nm); | 180 mJ | 500 µm spacing between mtz |
| M Abdallah | (3 stacks, | ||||||||
| 2 passes) | |||||||||
| Fire‐xel scanner system, Bison | |||||||||
| 2020 | 160 | Onychomycosis | Terbinafine 1% | 291.4 | Ointment | Once daily | CO2 (10,600 nm); | No fixed setting (dependent on heat sensation) | 1000–1500 µm spacing between mtz |
| B Rajbanshi | Wuhan Miracle Laser Co., Ltd. | ||||||||
| 2020 | 120 | Onychomycosis | Tioconazole 28% | 387.7 | Solution | Twice daily | CO2 (10,600 nm); SmartXide Square, DEKA, Florence, Italy | Power of 10–15 W (according to nail thickness), 3 stacks, pulse duration of 500 μs | 700–800 μm spacing between mtz |
| AM Zaki | |||||||||
| 2021 | 78 | Onychomycosis | Amorolfine 5% | 317.5 | Lacquer | Twice weekly | Er:YAG (2,940 nm); | 35–60 J cm−2 (dependent on nail thickness and patient tolerability) | 120 spots cm−2 |
| Sciton | |||||||||
| J Zhang | |||||||||
| 2021 | 22 | Nail psoriasis | Calcipotriol 50 μg/g + Betamethasone 0.5 mg/g | 392.5 + 412.6 | Gel | Once daily | CO2 (10,600 nm) | 60–110 mJ (dependent on patient tolerability) | 3% |
| Ultrapulse Encore, Lumenis Ltd. | |||||||||
| W Shehadeh | |||||||||
| 2021 | 27 | Nail psoriasis | Tazarotene 0.1% | 351.5 | Gel | Once daily | CO2 (10,600 nm); | 140 mJ | 150 spots cm−2 |
| N Essa Abd Elazim | Daeshin Enterprise Co., Ltd. Model: Multixel | 2–3 passes | |||||||
| 2014 | 1 | Healthy | Saline | 58.4 | Solution | Once (<5 min) | CO2 (10,600 nm); | 20–50 mJ | 10% |
| UltraPulse Encore Active FXTM; Lumenis | |||||||||
| CH Yang | |||||||||
| 2016 | 3 | Healthy | Sulconazole 1% | 460.8 | (a) Solution | Once (<5 min) | CO2 (10,600 nm); | 20–50 mJ | N.A. |
| UltraPulse Encore Active FXTM | |||||||||
| (b) Cream | |||||||||
| MT Tsai | |||||||||
| 2017 | 3 | Healthy | Caffeine 20 mg/mL | 194.2 | Solution | Once (72 h) | YDFL (532 nm) | 31–250 mJ pore−1 | 500 spots cm− 2 |
| Fianium FP‐1060‐5‐FS | |||||||||
| S Vanstone | |||||||||
| 2019 | N.A. | Healthy | Methylene Blue 0.5%–3% | 319.9 | Gel | Before irradiation (dual stage LADD) | Er:YLF (2,810 nm); | 3.9–4.1 mJ | N.A. |
| AV Belikov | – | ||||||||
| 2019 | N.A. | Healthy | (a) Amorolfine 5% | (a) 317.5 | Lacquer | Once (24 h) | CO2 (10,600 nm); | 50–80 mJ | N.A. |
| (b) Amorolfine 5% + Thioglycolic acid 5% | (b) +92.1 | Candela CO2RE laser, Syneron Candela, Wayland, MA, USA | |||||||
| (c) Amorolfine 5% + Urea 5% | (c) +60.6 | ||||||||
| I Sveikauskaite | |||||||||
| 2020 | N.A. | Healthy | (a) Naftifine 5% | (a) 323.9 | Lacquer | Once (24 h) | CO2 (10,600 nm); | 50–80 mJ | N.A. |
| Candela CO2RE laser, Syneron Candela, Wayland, MA, USA | |||||||||
| (b) Naftifine 5% + Thioglycolic acid 5% | (b) +92.1 | ||||||||
| (c) Naftifine 5% + Salicylic acid 0.5% | (c) +138.1 | ||||||||
| I Sveikauskaite | |||||||||
| 2021 | 5 | Healthy | Methylene Blue 0.001% | 319.9 | Solution | Before irradiation (dual stage LADD) | Er:YLF (2,810 nm); | 1–4 mJ | N.A. |
| AV Belikov | – |
Abbreviations: ALA, 5‐Aminolevulinic acid; LADD, laser‐assisted drug delivery; MAL, methyl aminolevulinate; mtz, microthermal zone.
Protocol only; study results published as thesis.
plus 595‐nm PDL (Perfecta, Syneron‐Candela) on nail folds.
Ytterbium‐doped fiber laser with frequency doubling lithium triborate crystal.
Figure 1Scanning electron microscopy image of healthy nail tissue exposed to 80 mJ/mb of ablative fractional CO2 laser (left: side view, right: top view). Images show complete poration of the nail plate and porous surface structure of the ablation zone
Figure 2Coherent anti‐Stokes Raman scattering microscopy image of a nail plate following 80‐mJ/mb AFL processing. While autofluorescence (top left, green pseudocolor) is seen mainly in the laser channel as well as the thermally affected ventral nail layer and the surface of the dorsal layer, the water (mid‐left, blue pseudocolor) and lipid (bottom left, red pseudocolor) content are restricted to the middle portion of the nail plate. The overlay (right) shows a trilaminar structure. AFL, ablative fractional laser
Overview of morphometric microscopy measurements of nail tissue sections presented as means and standard deviations
| Sample | Number of samples (sections) | Nail thickness (SD) | Ablation depth (SD) | Degree of poration (SD) |
|---|---|---|---|---|
| ATTO‐647N‐labeled fungal nail with AFL | 6 (54) | 607 µm (163 µm) | 195 µm (59 µm) | 35% (16%) |
| ATTO‐647N‐labeled healthy nail with AFL | 6 (54) | 372 µm (75 µm) | 199 µm (56 µm) | 56% (21%) |
| Unlabeled healthy nail with AFL | 3 (27) | 450 µm (80 µm) | 163 µm (53 µm) | 38% (15%) |
| ATTO‐647N‐labeled fungal nail | 6 (54) | 572 µm (266 µm) | ‐ | ‐ |
| ATTO‐647N‐labeled healthy nail | 6 (54) | 487 µm (98 µm) | ‐ | ‐ |
| Unlabeled healthy nail | 3 (27) | 476 µm (143 µm) | ‐ | ‐ |
Abbreviations: AFL, ablative fractional laser; SD, standard deviation.
Figure 3Overlay of UV (grayscale) and ATTO‐647N fluorescence (red pseudocolor) microscopy images of sections of intact and laser‐processed nail tissue. Healthy nail shows modest diffusion of ATTO‐647N seen primarily in the top layer (A), with a visible overall increase of signal intensity and wider distribution after fractional ablative laser treatment (B). In fungal nail tissue, ATTO‐647N diffuses more easily into deeper layers (C) with increased signal intensity in the top layer after laser processing (D)
Overview of the average nail plate ATTO‐647N fluorescence signal intensity (values in arbitrary units)
| Sample | Number of samples (sections) | Mean | SD | Median | MAD | Minimum | Maximum | Range | IQR |
|---|---|---|---|---|---|---|---|---|---|
| ATTO‐647N‐labeled fungal nail | 6 (54) | 305.4 | 307.5 | 167.7 | 92.0 | 102.1 | 1720.4 | 1618.3 | 228.0 |
| ATTO‐647N‐labeled healthy nail | 6 (54) | 146.3 | 68.6 | 117.1 | 20.4 | 100.8 | 502.2 | 401.5 | 48.2 |
| ATTO‐647N‐labeled fungal nail with AFL | 6 (54) | 428.1 | 421.8 | 273.8 | 195.2 | 102.2 | 2603.8 | 2501.5 | 324.9 |
| ATTO‐647N‐labeled healthy nail with AFL | 6 (54) | 308.2 | 248.8 | 202.0 | 128.0 | 102.3 | 1564.1 | 1461.8 | 270.7 |
| Unlabeled healthy nail | 3 (27) | 102.2 | 0.5 | 102.1 | 0.5 | 101.4 | 103.3 | 1.9 | 0.6 |
| Unlabeled healthy nail with AFL | 3 (27) | 103.2 | 1.0 | 103.0 | 1.0 | 101.7 | 106.6 | 4.9 | 1.3 |
Abbreviations: IQR, interquartile range; MAD, median absolute deviation; SD, standard deviation.
Pairwise comparison of ATTO‐647N fluorescence signal intensities using Wilcoxon rank‐sum test with continuity correction (Hochberg p value adjustment)
| Samples | ATTO‐647N‐labeled fungal nail | ATTO‐647N‐labeled healthy nail | ATTO‐647N‐labeled fungal nail with AFL | ATTO‐647N‐labeled healthy nail with AFL |
|---|---|---|---|---|
| ATTO‐647N‐labeled fungal nail | <0.0001 | <0.0001 | <0.0001 | |
| ATTO‐647N‐labeled healthy nail | <0.0001 | <0.0001 | <0.0001 | |
| ATTO‐647N‐labeled fungal nail with AFL | <0.0001 | <0.0001 | <0.0001 | |
| ATTO‐647N‐labeled healthy nail with AFL | 0.09 | <0.0001 | <0.0001 |
Figure 4Faceted boxplot showing ATTO‐647N fluorescence intensities measured in the dorsal, intermediate, and ventral portion of healthy and fungal nail samples with and without ablative fractional laser pretreatment
Mean ATTO‐647N fluorescence signal intensities (values in arbitrary units) for each nail plate layer.
| Nail plate layer | Unlabeled healthy nail | Unlabeled healthy nail with AFL | ATTO‐647N‐labeled healthy nail | ATTO‐647N‐labeled healthy nail with AFL | ATTO‐647N‐labeled fungal nail | ATTO‐647N‐labeled fungal nail with AFL |
|---|---|---|---|---|---|---|
| Top layer | 102.2 | 103.2 | 198.7 | 442.0 | 448.3 | 758.9 |
| Middle layer | 102.2 | 103.3 | 126.2 | 252.0 | 254.8 | 294.9 |
| Bottom layer | 102.1 | 103.0 | 114.0 | 230.6 | 216.4 | 243.5 |
Percentage change of ATTO‐647N fluorescence signal intensity in healthy and fungal ex vivo nail tissue
| Nail plate layer | Increase in healthy nail after AFL | Increase in fungal nail after AFL | Increase in signal due to infection (healthy vs. fungal) |
|---|---|---|---|
| Top layer | +122% | +69% | +126% |
| Middle layer | +100% | +16% | +102% |
| Bottom layer | +102% | +13% | +90% |
| Average | +108% | +33% | +106% |